. The Ma rch 1989 simultaneous binaura l bithen nal test revea ls an abnorma l RVR lef t.
A 32-year-old man made his first visi t to the office on March 13, 1989 , and related a history of dizz iness and tinn itus that had beg un in Decemb er 1987. In January 1988, he had undergone electronystagmography (ENG) at another fac ility, but no abnormality was evident. The alternate bina ural bither mal test at that time detected a reduced vestibular response (RVR) of 16% left and a direc tional prepond erance (DP) of 8% right-both within normal limits.
The patient describ ed his sensation as a feeling of floating, and he said that he was co ntinually "catching" himself to kee p from falling. His loss of balance wo uld become more pro nounce d later in the day as he beca me fatigued. Th ere was no rotary compo nent to his sym ptoms. His tinn itus was inter mitte nt in both ears and stro nger on the left. He described his tinnit us as a "pinging" in the left ear and a "thumping" in the right. He experienced neither aura l fulln ess nor hearing loss. He thought his co ndition must be psychosomatic because his previous ENG had been norm al.
The results of a clin ical neurotologic exa mination were normal, as were findings on a follow -up alterna te binaur al bithermal test. However, a simultaneous binaural bithermal test revealed an abnormal RVR left (figure 1). Moreover, From Ncurotologic Associates, P.c., New York City. 616 the patient' s response to a 5-hour glucose tolerance test was exaggerated, and ' his level of circ ulating immune co mplexes of the Raji cell type was markedl y eleva ted. Magnetic reso nance imagin g, with and withou t gadolinium enhanceme nt, detected no abnormality, but polytom ography of the temp oral bones revealed ev idence co nsistent with labyri nth ine otosclerosis. Th e patient was placed on a diet to address metabolic fac tors , and he was presc ribed sodium fluor ide and ca lcium carbonate to add ress the otoscle rosi s.
Despite 3 month s of this thera py, the pat ient experienced no change in,his symptoms, and his Raji cell count was still eleva ted . He was also eva luated by an immunologist, who discovered that the patient had an immun oglobulin A deficien cy.
A varie ty of vestibular suppressa nt med ications was tried without benefit. By December 1989, there had been no change in the pat ient ' s symptoms, and he returned to the office for re-evalua tion. He underwent a sinusoidal ver tica l-axis rotat ion test, and the findi ngs were normal. His Raji cell level had dro pped to normal, but a follow-up glucose tolerance test showed that his response was still exaggerated, although his insulin levels were normal. Follow-up ENG yielded res ults similar to his previous tests. Findi ngs on the alternate binaur al bitherm al test were again within normal limits (RV R: 17%; DP : 7%), Babeprazote is metaboli zed by thecytochrome P450 (CYP450) drug metaboli zing enzyme system. Studies in healthy subjects have shown that rabep razole does not have clinically significant interactions with other drugs metabolized by the CYP450system. such aswarf arin andtheophylline given assingle oral doses, diazepam asa single intravenous dose. and phenytoin given asa si ngle intraveno usdose (wi th suppl emental oral dosing). St eady stateinteractions of rabeprazol e and other drugs metabolized by thi s enzyme system have not been studied in patients. Therehave been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including rabeprazole. and wartarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bl eedingand even death.
In vitro incubations empl oying human liver microsomes indicated that rabeprazole inhibited cycl osporine metabolism with an IC" of 62 micromolar, a concentration that is over 50 times higher than the C"", in healthy vol unt eers following 14days of dosing with 20 mg of rabeprazole. This degree of inhibitionissimi lar tothat by omeprazole at equivalentconcentrations. Rabeprazole produces sustai ned inhibi tion of gastric acid secretion. An interaction wi th compounds which are dependent on gastric pH for absorption may occur due to the magnitude of acid suppression observed with rabeprazole, For example, in normal subjects. co-administration of rabeprazole 20 mg 00 resulted in an approximately 30% decrease in the bioavailability of ketoconazol eand increases in theAU CandC"", fordigoxin of 19% and 29%. respectively. Therefore, pati ents may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-admini strationof rabeprazole and antacids produced no clinically relevantchanges in plasma rabeprazoleconcentrations.
In a clinical study in Japaneval uating rabeprazol e in pat ients categorized by CYP2C19genotype (n;6 per genotype category), gastric acid suppression was higher in poor rnetabolizers ascompared to extensi ve metabol izers. This could be due to higher rabeprazol e plasma levels in poor metabollzers. Whet her or notinteractions of rabeprazole sodium with other drugs metabol ized by CYP2C1 9 would bediflerent bet ween extensive met abolizers and poor met aboli zers has not been studied. Carcinogenesis, Mutagenesis, Impairment of Fertil ity In a 88/104-week carcinogenicitystudy in CD-l mice, rabeprazole at oral doses upto 100 mg/kg/day did not produce any increased tumor occurrence. The highest tested dose produced a systemic exposure to rabeprazol e (AUC) of 1.40 pg'hr/mL which is 1.6 times the human exposure (pl asma A U C O -~; 0.88 pg'hr/mL) at the recommended dose for GER D (20 mg/day Teratol ogy studies havebeen perf ormedin ratsat intravenousdoses upto 50mg/kg/day (plasma AUC of 11.8 pg'hr/mL, about 13 timesthe human exposure at the recommended dose for GERD) and rabbits at intravenous doses up to 30 mglkg/day (plasma AUC of 7.3 pg'hr/mL, about 8 times the human exposureat the recommended dose for GERD) and have reveal ed no evidence of impaired fertilityor harm to the fetus dueto rabeprazole. There are, however , noadequateandwell-controlled studi esin pregnant women. 8ecause animal reproduction studies arenot always predi ctive of human response, this drug should be used during pregnancy only if clearly needed. NursingMothers Following intravenous administration of "C-Iabeled rabeprazole to lactating rats, radi oactivity in mi lk reached levels that were 2-to 7-fold hi gher than levels in the blood. It is not known if unmetabolized rabeprazol e is excreted in human breast milk. Administration of rabeprazole to rats in late gestati on and dur inglactation at doses of 400 mglkg/day (about 195-times the human dose based on mg/m') resulted in decreases in body weight gain of the pups. Since many drugs are excreted in mi lk, and because of the potential for adverse reactions to nursing infants from rabeprazole, a decision should be made to discontinue nursing or discontinue the drug, taking intoaccount the importance of the drugtothe mother. Pediatric Use Thesafety and effectiveness otrabeprazolein pediatricpatients havenot been established. UseinWom en Duodenal ulcer and erosive esophagi tis healing rates in women are similar to thosein men. Adverse eventsand laboratorytest abnormalities inwomen occurredatrates similar to thoseinmen. Geriatric Use Of thetotal number of subjects in clinical studies ofACIPHEX' , 19%were65years and over, while4% were 75 years and over. No over alldifferences in safety or effectiveness wereobserved bet ween these subjects and younger subjects, and other reported clinical experiencehas not identified differences in responses between the el derly and younger patients, but greater sensitivityof some olderindividuals cannot beruled out. ADVERSEREACTIONS Worldwide, over 2900 patient s have been treated with rabeprazole in Phase II-III clinical trials involvi ngvariousdosages and durationsoftreatment.Ingeneral, rabeprazol etreatmenthas beenwelltolerated in bothshort-term and long-term trial s. The adverse events rates were generall y similar bet ween the10 and 20mg doses.
Incidence inControlled NorthAm ericanandEuropean Clinical Tri als
In an analysis of adverse events assessed as possibl y or probably rel ated to treatment appearing in greaterthan 1%of ACIPHEX' patientsand appearing withgreaterfrequency than pl acebo incontrol led North American and Eu ropean trials, the incidenceof headache was 2.4% (n; 1552) for ACIPHEX' versus 1.6% (n; 258) for placebo.
In short and long-term studies, the foll owing adverseevents,regardless of causality, werereported in AC IPHEX' -treatedpat ients. Rareeventsarethose reportedin~1 11 0 00 patients. ..····.·: ·. .· · · · · · ·~..·..··..·· · · · · · · · ..······ ·: 1 : ·····..1 :······..·· · · · · · · ·· · · · ..· : : : . : :
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. . .. !. ... :.j. . . .~.. . . ; j""" i. . ·. . ·. . · : · · .~; . and the simultaneous binaural bithermal test showed an RVR left as before (figure 2). There was no spontaneous or positional nystagmus. The patient continued on his drug regimen through 1993 without significant improvement. In the meantime, he underwent computed dynamic posturography in 1991, but it failed to identify any abnormality.
The patient finally became free of symptoms in the spring of 1994, and he remained asymptomatic for 18 months. However, on Nov. 1, 1995, he returned to the office following a recurrence. He reported that "things began tilting to the left" 4 weeks earlier and that his vestibular symptoms and tinnitus had returned; he said that the thumping had become more noticeable and that it was now present in both ears, more so on the left. To treat the otosclerosis, he was placed on a pulsed-dose regimen of etidronate (a bisphosphonate), and he continued on sodium fluoride and calcium carbonate. He later reported that he would experience a feeling of rotation while taking etidronate and that he felt better when he was off it. Over the following 7 months , the patient's spinning feeling eventually disappeared.
The patient's other vestibular symptoms persisted until October 1997, when he again became almost free of symptoms. However, by July 1998 he had again been experiencing balance problems for several months, although he had no rotary vertigo. He was switched from pulsed-dose etidronate to daily alendronate (another bisphosphonate). At first the alendronate provoked more symptoms, but they diminished over time. However, the symptoms again recurred after the patient had received an influenza vaccination.
During 1999, the patient's symptoms slowly abated, and by August 2000, they had again disappeared. In December 2001, he was switched to risedronate, another bisphosphonate that allows for twice-weekly dosing .
In retrospect, this patient had a left peripheral vestibular disorder that was detected only by the simultaneous binaural bithermal test. Otosclerosis was the cause of the mismatched input into the central nervous system. It was not until he began taking bisphosphonates, especially the newer ones, that his symptoms were eventually brought under control. 
